Locations:
Search
Cleveland Clinic Innovations returned from BIO 2025 in Boston with valuable insights and promising opportunities following strategic partnering meetings that demonstrated the biotech industry's continued appetite for quality innovation. The team identified emerging growth areas in cardio-metabolic therapies and Women's Health, while connecting with leading pharmaceutical companies eager for deeper collaborative partnerships. The conference reinforced that today's biotech landscape rewards comprehensive partnerships that leverage Cleveland Clinic's unique position as an innovation powerhouse combining breakthrough science with clinical expertise.
Investment Landscape: Selective but Strategic
While biotech funding remains challenging, Hunter Rogers, PhD, Principal, Innovations Ventures, observed that quality science continues to find support. "It not only remains difficult for biotech companies to secure funding, but it is also tougher for biotech-focused venture capital funds to fundraise," Rogers noted. "But good science is still getting funded, just in more disciplined and creative ways."
Linda Li, MSc, CFA, Partner, Innovations Ventures, emphasized the stark funding contrast across development stages, noting "seed-stage investors are still interested and active about preclinical proof of concept stage companies if it's novel, but later stage companies definitely see the funding gap. This is one of the coldest times in recent years." However, promising opportunities remain, with some venture firms still actively deploying capital to bridge the early innovation funding gap.
Emerging Therapeutic Focus Areas and Technology Trends
Despite funding challenges, certain areas are attracting renewed investor interest. Rogers identified two key growth areas, "One is the cardiometabolic space, beyond GLP-1s, the second is Women's Health, where people have clearly identified the huge unmet needs that remain due to the historical lack of funding that's gone into even basic research."
The largest areas of interest remain oncology, inflammation/immunology, and neurology, consistent with traditional powerhouse areas that continue to dominate investor focus. However, there's a notable preference for established modalities, with many companies favoring "tried-and-true small molecule and antibody therapies, citing undesirable modality risk in a risk-off environment" with newer approaches.
Interest in new modalities was primarily niche and company-specific. Gene therapy faces particular scrutiny following recent clinical safety events and rising costs, while cell and gene therapy generated mixed responses overall. Emerging areas that captured attention included novel technologies for oligonucleotide delivery and brain delivery systems.
Geographic Variations and Market Dynamics
Saqib Sachani, PhD, MBA, Director, Innovations Business Development and Licensing, noted important geographic market variations regarding vaccines, "We're seeing strong international demand and acceptance for vaccines and infectious disease solutions for emerging pathogens, which presents significant opportunities for global expansion."
The conference demonstrated higher acceptance rates from major strategic pharmaceutical companies, indicating continued interest from large pharma in partnership opportunities. Additionally, companies showed sustained interest in academic centers' ability to support clinical activities through data partnerships.
Partnership Evolution: Comprehensive Collaboration
The most significant shift involves partnership expectations. "From an overall partnership perspective, they are not looking for transactional deals where they license and walk away. It's more on collaboration," Sachani explained.
This trend requires a new approach, "We should consider packaging not just the technologies as a solo, but packaging our brand, technology, KOLs, our facilities, everything together as a package deal to enhance the collaborative elements," Sachani recommended.
Cleveland Clinic's Unique Position
BIO reinforced Cleveland Clinic's distinctive market position. "Cleveland Clinic goes beyond what most tech transfer offices do. We have an integrated system to sponsor the technology from development to commercialization and also provide funding when the market is still observing.," Li noted.
Sachani emphasized this differentiation, "We call ourselves the innovation powerhouse because we are doing a lot more things than just tech transfer work."
Strong Performance and Engagement
The team's BIO 2025 presence generated results across multiple dimensions, with the team engaging in meaningful connections with pharmaceutical companies, biotech firms, and investors.
Julie Woda, PhD, Senior Director, Innovations Proof of Concept, noted the conference's exceptional value, "It was a really good conference. We received a lot of interest in our programs, and met pharma, biotech and investors." The team gained crucial insights into current areas of interest while engaging with companies involved in cutting-edge technologies.
The conference reinforced Cleveland Clinic Innovations' position as a strategic partner for advancing breakthrough therapies from bench to bedside, demonstrating the organization's continued relevance in an evolving biotech landscape.
